White Space

In the Molecular Target / Antigen dimension, coverage is sharply concentrated around PSMA, which appears in 29 of 115 projects (25.2% of sample) - more than any other individual target and roughly 6x the next largest classified target, androgen receptor/androgen signaling at 5 projects (4.3%). The remaining named targets - CD46, DLL3/neuroendocrine markers, TGF-beta, HER2, STEAP, integrin/ECM targets, and multi-target/bispecific approaches - each appear in 0 to 4 projects, collectively reflecting thin but distributed interest in non-PSMA antigen space. Forty-three of 115 projects are unclassified in this dimension, suggesting a portion of the sample addresses targeting concepts not easily mapped to a single antigen category.

The Radionuclide / Emission Type dimension has the highest unclassified rate of all five dimensions - 71 of 115 projects (61.7%) - indicating that a majority of projects in this sample do not foreground a specific isotope in their title or abstract. Among the 44 classified projects, Lutetium-177 dominates at 22 projects (19.1% of sample), followed by Actinium-225 at 9 projects (7.8%), reflecting the field's clinical and preclinical investment in these two isotopes. The Lead-212/Lead-203 theranostic pair appears in 4 projects (3.5%), while Bismuth-212/213, Yttrium-90, and several novel/emerging radionuclides each appear in 0 or 1 projects - counts too sparse to draw coverage conclusions beyond noting they are minimally represented in this sample.

In the Therapeutic Strategy / Combination Approach dimension, radioligand therapy monotherapy optimization is the dominant category at 34 projects (29.6% of sample), and theranostic paired imaging and therapy is a substantial secondary cluster at 21 projects (18.3%) - each cited separately as they are non-exclusive rows. Combination strategies such as RLT + immunotherapy (2 projects, 1.7%), RLT + external beam radiotherapy (3 projects, 2.6%), RLT + vaccine approaches (3 projects, 2.6%), RLT + ADC (2 projects, 1.7%), and radiosensitization (5 projects, 4.3%) are each present but thinly represented relative to the monotherapy and theranostic clusters. The broader NIH count for theranostic paired imaging (64) is notably elevated relative to peer categories in this dimension - this count likely reflects the term's prevalence across cancer imaging broadly and should be treated as directional rather than topic-specific.

The Cancer Type / Disease Context dimension has 52 of 115 projects unclassified, and among the 63 matched, hormone-sensitive prostate cancer is the most represented sub-type at 16 projects (13.9% of sample), while mCRPC - the disease context most associated with approved RLT agents - registers 0 projects in this sample (0.0%). Several off-prostate disease contexts appear (lung cancer at 4 projects, 3.5%; pancreatic cancer at 3 projects, 2.6%; bone metastases at 3 projects, 2.6%; neuroendocrine prostate cancer at 3 projects, 2.6%), reflecting interest in extending RLT platforms beyond primary prostate indications. The broader NIH count for mCRPC (65) stands out as the highest in this dimension and is substantially above the median for peer categories, which warrants attention but is addressed in the ranked opportunities section rather than as a dimension-level conclusion.

The Translational / Development Dimension has the highest match rate of all five dimensions at 93 of 115 projects, indicating that most projects in this sample can be assigned a translational stage or focus. Ligand/radiopharmaceutical design and synthesis is the most common category at 33 projects (28.7% of sample), followed by preclinical in vivo/animal model studies at 21 projects (18.3%) - each cited separately as rows are non-exclusive. Biomarker-guided patient selection and personalization (8 projects, 7.0%), resistance mechanisms and tumor microenvironment (5 projects, 4.3%), and artificial intelligence/computational methods (1 project, 0.9%) are each underrepresented relative to the upstream chemistry and preclinical clusters, suggesting the sample skews toward early-stage research rather than clinical translation, personalization, or computational optimization.